Recs

7

Let That Shell Lie

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

With crude prices inching their way higher, I'm finding the Big Oil companies steadily more compelling. But Royal Dutch Shell (NYSE: RDS-A  ) (NYSE: RDS-B  ) , for one, has never been at the top of my hit parade, even though I once toiled for a company that subsequently was bought by Shell.

One of the reasons I haven't been high on the company for the past several years was the 2004 padding of reserves -- a stunt that cost it $350 million in fines -- a lot of money before the days of bailouts. But beyond that, Shell has never appeared as well run as European neighbors Total (NYSE: TOT  ) ; or more recently, BP (NYSE: BP  ) ; and perhaps even StatoilHydro (NYSE: STO  ) . Now, however, we've been informed that Shell is being redone, both structurally and managerially.

Let's hope the redo works, since it apparently will affect all of the company. For starters, Peter Voser, Shell's CFO, will replace CEO Jeroen van der Veer on July 1, when the entire changeover will occur. Voser topped his two rivals, Linda Cook and Malcolm Brinded, for the position. Ms. Cook, who has been with the company for nearly 30 years and has headed its gas and power division for the past five years, will resign on Monday.

In the upstream, the three units -- exploration and production, gas and power, and oil sands -- will be reduced to Upstream Americas and Upstream International. Beyond that, a new business, Projects & Technology, is being hatched to coordinate a variety of technology activities that had previously been scattered throughout the company. The downstream unit -- which has included refining, marketing, and chemicals -- will now add trading and alternative energy, except for wind, which will become a part of upstream operations.

It also appears that, as with so many companies, there will be employee layoffs estimated at possibly 20% of Shell’s back-office staff. And as Voser noted in describing the changes, “the industry, and Shell, faces considerable challenges, from high costs, volatile energy prices, and competition for new projects.”

So should we be buying Shell on this news? My response is a fairly resounding "nein!" It could easily be a while before the wrinkles are ironed out of the new structure, which seems a mite experimental. Beyond that, I’d rather own ExxonMobil (NYSE: XOM  ) or perhaps even a Chevron (NYSE: CVX  ) over even a newly polished Shell.  

For related Foolishness:

Best Odds in the Universe!
If you're interested in a 98.79% chance at beating the market... and a 70.84% chance at DOUBLING the market's return – Motley Fool Supernova could be just what you're looking for. And get this: We arrived at these odds from 10,000 random back-tested portfolios composed of Motley Fool Co-founder David Gardner's personal stock picks.

It's why David recently handpicked a small team of world-class portfolio managers. You see, he thinks these odds can get even better! And he'd like to prove it to you...

Simply enter your email address. And the answer to the question everybody is asking will be delivered to your inbox!

StatoilHydro ASA and Total SA are Motley Fool Income Investor selections. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor David Lee Smith doesn't own shares in any of the companies mentioned. He does, however, welcome your questions or comments. The Motley Fool has a disclosure policy that needs no restructuring.


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 29, 2009, at 2:12 AM, luvit1 wrote:

    And let's not forget their trial for aiding and abetting the Nigerian gov't in executing protesters for trying to preserve their part of the country. And their role in the slaughter of many innocent Nigerians. Need to buy stocks with some sense of ethics and morality and not just their financial situation.

  • Report this Comment On May 29, 2009, at 8:59 AM, TMFMarlowe wrote:

    Good article and I agree, having gone through this exercise a few months back. RDS looks interesting at first glance, but there are much more compelling arguments for XOM or TOT or BP.

    FWIW, I ended up buying BP -- I felt it had a slight value edge over the others at the moment I was investing -- but I would have been happy to own either of the other two.

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 908888, ~/Articles/ArticleHandler.aspx, 2/10/2012 8:42:03 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 12,801.23 -89.23 -0.69%
S&P 500 1,342.64 -9.31 -0.69%
NASD 2,903.88 -23.35 -0.80%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

2/10/2012 4:04 PM
RDS-B $72.74 Down -1.04 -1.41%
Royal Dutch Shell CAPS Rating: *****
RDS-A $72.05 Down -0.73 -1.00%
Royal Dutch Shell… CAPS Rating: ****
TOT $53.65 Down -0.88 -1.61%
Total SA. (ADR) CAPS Rating: *****
XOM $83.80 Down -1.08 -1.27%
ExxonMobil Corp CAPS Rating: ****
STO $27.10 Up +0.36 +1.35%
Statoil (ADR) CAPS Rating: *****
BP $46.35 Down -0.42 -0.90%
BP p.l.c. (ADR) CAPS Rating: ****
CVX $105.28 Down -1.09 -1.02%
Chevron Corp CAPS Rating: *****

Advertisement